L
Lena M. Kranz
Researcher at University of Mainz
Publications - 33
Citations - 4944
Lena M. Kranz is an academic researcher from University of Mainz. The author has contributed to research in topics: Immune system & Immunotherapy. The author has an hindex of 14, co-authored 33 publications receiving 2393 citations. Previous affiliations of Lena M. Kranz include German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Carsten Boesler,Corinna Rosenbaum,Marie Cristine Kühnle,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +41 more
TL;DR: The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Journal ArticleDOI
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz,Mustafa Diken,Heinrich Haas,Sebastian Kreiter,Carmen Loquai,Kerstin C. Reuter,Martin Meng,Daniel Fritz,Fulvia Vascotto,Hossam Hefesha,Christian Grunwitz,Mathias Vormehr,Yves Hüsemann,Abderraouf Selmi,Andreas Kuhn,Janina Buck,Evelyna Derhovanessian,Richard Rae,Sebastian Attig,Jan Diekmann,Robert A. Jabulowsky,Sandra Heesch,Jessica C. Hassel,Peter Langguth,Stephan Grabbe,Christoph Huber,Özlem Türeci,Ugur Sahin +27 more
TL;DR: It is shown that DCs can be targeted precisely and effectively in vivo using intravenously administered RNA-lipoplexes (RNA-LPX) based on well-known lipid carriers by optimally adjusting net charge, without the need for functionalization of particles with molecular ligands.
Journal ArticleDOI
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Ugur Sahin,Alexander Muik,Isabel Vogler,Evelyna Derhovanessian,Lena M. Kranz,Mathias Vormehr,Jasmin Quandt,Nicole Bidmon,Alexander Ulges,Alina Baum,Kristen E. Pascal,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Peter Koch,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Manuel Tonigold,Carsten Boesler,Corinna Rosenbaum,Ludwig Heesen,Marie Cristine Kühnle,Asaf Poran,Jesse Z. Dong,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Tania Palanche,Armin Schultz,Sybille Baumann,Azita J. Mahiny,Gábor Boros,Jonas Reinholz,Gábor Szabó,Katalin Karikó,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Mark Cutler,David A. Cooper,Christos A. Kyratsous,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +48 more
TL;DR: BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) that encodes the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy in preventing coronavalirus disease-19 (COVID-19)1 as mentioned in this paper.
Journal ArticleDOI
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Ugur Sahin,Petra Oehm,Evelyna Derhovanessian,Robert A. Jabulowsky,Mathias Vormehr,Maike Gold,Daniel Maurus,Doreen Schwarck-Kokarakis,Andreas Kuhn,Tana Omokoko,Lena M. Kranz,Mustafa Diken,Sebastian Kreiter,Heinrich Haas,Sebastian Attig,Richard Rae,Katarina Cuk,Alexandra Kemmer-Brück,Andrea Breitkreuz,Claudia Tolliver,Janina Caspar,Juliane Quinkhardt,Lisa Hebich,Malte Stein,Alexander Hohberger,Isabel Vogler,Inga Liebig,Stephanie Renken,Julian Sikorski,Melanie Leierer,Verena Müller,Heidrun Mitzel-Rink,Matthias Miederer,Christoph Huber,Stephan Grabbe,Jochen Utikal,Andreas Pinter,Roland Kaufmann,Jessica C. Hassel,Carmen Loquai,Özlem Türeci +40 more
TL;DR: Results of an exploratory interim analysis from a phase I trial show that an RNA vaccine targeted towards four melanoma-associated antigens produces durable objective responses in patients with melanoma that are accompanied by strong CD4 + and CD8 + T-cell immunity.
Journal ArticleDOI
BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
Annette B. Vogel,Isis Kanevsky,Ye Che,Kena A. Swanson,Alexander Muik,Mathias Vormehr,Lena M. Kranz,Kerstin C. Walzer,Stephanie Hein,Alptekin Güler,Jakob Loschko,Mohan S. Maddur,Ayuko Ota-Setlik,Tompkins Kristin Rachael,Journey Cole,Bonny Gaby Lui,Thomas Ziegenhals,Arianne Plaschke,David Eisel,Sarah C. Dany,Stephanie Fesser,Stephanie Erbar,Ferdia Bates,Diana Schneider,Bernadette Jesionek,Bianca Sänger,Ann Kathrin Wallisch,Yvonne Feuchter,Hanna Junginger,Stefanie A. Krumm,Andre P. Heinen,Petra Adams-Quack,Julia Schlereth,Stefan Schille,Christoph Kröner,Ramón de la Caridad Güimil Garcia,Thomas Hiller,Leyla Fischer,Rani S. Sellers,Shambhunath Choudhary,Olga Gonzalez,Fulvia Vascotto,Matthew R. Gutman,Jane Fontenot,Shannan Hall-Ursone,Kathleen M. Brasky,Matthew C. Griffor,Seungil Han,Andreas A.H. Su,Joshua A. Lees,Nicole L. Nedoma,Ellene H. Mashalidis,Parag Sahasrabudhe,Charles Tan,Danka Pavliakova,Guy Singh,Camila R. Fontes-Garfias,Michael W. Pride,Ingrid L. Scully,Tara Ciolino,Jennifer Obregon,Michal Gazi,Ricardo Carrion,Kendra J. Alfson,Warren Kalina,Deepak Kaushal,Pei Yong Shi,Thorsten Klamp,Corinna Rosenbaum,Andreas Kuhn,Özlem Türeci,Philip R. Dormitzer,Kathrin U. Jansen,Ugur Sahin +73 more
TL;DR: In this article, the authors report the preclinical development of two vaccine candidates (BNT162b1 and BNT 162b2) that contain nucleoside-modified messenger RNA that encodes immunogens derived from the spike glycoprotein (S) of SARS-CoV-2, formulated in lipid nanoparticles.